Literature DB >> 18421241

Animal models of intraocular lymphomas.

Valérie Touitou1, Bahram Bodaghi, Yvonne de Kozak, Phuc Lehoang, Catherine Sautès-Fridman, Sylvain Fisson.   

Abstract

Primary intraocular lymphoma is a high-grade non-Hodgkin lymphoma whose pathogenesis is still unclear. Few animal models exist in order to study this condition. Although intraocular lymphomas in humans are usually B cell lymphomas, most of these models are T cell lymphomas. Recently, a major step forward has been realized with the development of new models of intraocular B cell lymphoma. New therapeutic tools are being evaluated in these models of B cell lymphoma. We evaluate the contribution of the different animal models available to study intraocular lymphomas, and we discuss the new therapeutic strategies and their various targets in the tumor as well as in the environment, which are currently investigated through the development of these models. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18421241     DOI: 10.1159/000119878

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  3 in total

1.  The future of primary intraocular lymphoma (retinal lymphoma).

Authors:  Chi-Chao Chan; Sylvain Fisson; Bahram Bodaghi
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

Review 2.  Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies.

Authors:  Rym Ben Abdelwahed Bagga; Sabrina Donnou; Jérémie Cosette; Catherine Sautès-Fridman; Mahjoub Aouni; Sylvain Fisson
Journal:  J Neurooncol       Date:  2014-10-10       Impact factor: 4.130

3.  Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma.

Authors:  Claire Galand; Sabrina Donnou; Lucile Crozet; Séverine Brunet; Valérie Touitou; Hanane Ouakrim; Wolf Herman Fridman; Catherine Sautès-Fridman; Sylvain Fisson
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.